Table 1 Patient and tumor baseline characteristics
Internal cohort | Test cohort A | Test cohort B | P | |||
|---|---|---|---|---|---|---|
Training cohort | Validation cohort | |||||
Subject | 618 | 154 | 156 | 123 | ||
Malignant | ||||||
Age | 49.1 (± 16.1) | 51.0 (± 12.2) | 47.4 (± 12.0) | 49.1 (± 16.1) | 0.91 | |
Gender | Male | 17 (53.1%) | 4 (50.0%) | 2 (40.0%) | 4 (40.0%) | 0.431 |
Total | 32 | 8 | 5 | 10 | ||
Benign | ||||||
Age | 33.9 (± 9.0) | 32.7 (± 7.9) | 32 (± 7.5) | 33.9 (± 9.0) | 0.02 | |
Gender | Male | 288 (49.2%) | 69 (47.3%) | 80 (53.0%) | 59 (52.2%) | < 0.001 |
Type | 0.028 | |||||
Lipomyoma | 121 (20.6%) | 30 (20.5%) | 40 (26.5%) | 28 (24.8%) | ||
Hemangioma | 120 (20.5%) | 30 (20.5%) | 16 (10.5%) | 20 (17.7%) | ||
Neurinoma | 120 (20.5%) | 30 (20.5%) | 25 (16.6%) | 18 (15.9%) | ||
Epidermal cyst | 160 (27.3%) | 40 (27.4%) | 45 (29.8%) | 27 (23.9%) | ||
Calcifying epithelioma | 65 (11.1%) | 16 (11.1%) | 25 (16.6%) | 20 (17.7%) | ||
Total | 586 | 146 | 151 | 113 | ||